Device Trial Radar · NCT07556809
Exoskeleton Gait Training in Guillain-Barré Syndrome: Safety, Feasibility, Usability, and Longitudinal Outcomes
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Aug 7, 2023
Primary completion
Dec 12, 2025
Study completion Dec 12, 2025
Sponsor
- Lead sponsor
- Institut GuttmannAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Wandercraft
- First posted
- Apr 29, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of the study is to determine if the Atalante X exoskeleton by Wandercraft is a safe, reliable, and usable device for people with Guillain-Barré Syndrome (GBS) who are unable to walk. The secondary objective is to assess the impact of using this device on the gait and functional recovery of this type of users (GBS). The users undergo 20 training sessions over 6 weeks. Assessments are carried out at baseline, post-intervention, and at a 4-week follow-up after completing the training sessions. In all assessments, the same outcomes is conducted using the Medical Research Council Outcome, 10-Meter Walk Test, 6-Minute Walking Test, Kansas University Standing Balance Scale, Functional Independence Measure and Level of Assistence. To assess satisfaction, the QUEST 2.0 scale is administered. During this 20 sessions, monitoring is conducted for possible adverse effects that may appear and for the time required for donning and doffing the device.
Conditions
- Guillain Barré Syndrome
Interventions
Exoskeleton Wandercraft Atalante X, usability and gait rehabilitationDevice
Exoskeleton Wandercraft Atalante X trainning in Guillain Barre syndrome
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety deviceTime frame: From baseline to the Week 6(end of intervention).
- FesabilityTime frame: From baseline to the Week 6 (end of intervention).
- Usability and satisfactionTime frame: From baseline to the week 3 (10 session).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institut Guttmann
Badalona, Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.